An estradiol matrix transdermal system for the prevention of postmenopausal bone loss

Clinical Therapeutics

Volumn 22, Issue 7, 2000, Pages 845-857

  McKeever, Clark ^a   McIlwain, Harris ^b   Greenwald, Maria ^c   Gupta, Niroo ^d   Jayawardene, Sumedha ^d   Huels, Gabriele ^d   Roberts, Maria ^d  

^a Health Advance Institute   (United States)

^b Tampa Medical Group   (United States)

^c Osteoporosis Medical Center   (United States)

^d NOVARTIS PHARMA AG   (Switzerland)

Author keywords

Bone loss; Bone mineral density; Estradiol matrix; Menopause; Osteoporosis; Transdermal

Indexed keywords

ESTRADIOL; MEDROXYPROGESTERONE ACETATE;

ARTICLE; BONE DENSITY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERANCE; ESTROGEN THERAPY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MULTICENTER STUDY; POSTMENOPAUSE OSTEOPOROSIS; RANDOMIZED CONTROLLED TRIAL;

EID: 0033873469     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/S0149-2918(00)80057-0     Document Type: Article

References (19)

1. Assessment of fracture risk and its application to screening for postmenopausal osteoporosis: Report of WHO study group
2. Estrogens, the menopause, and osteoporosis
3. Therapeutic controversy: Estrogen replacement in menopause
4. The menopause and osteoporosis
5. The role of estrogen in the prevention of osteoporosis
6. European and North American experience with HRT for the prevention of osteoporosis
7. Diagnosis, prophylaxis, and treatment of osteoporosis
8. Pharmacology and pharmacokinetics of estrogens
9. Pharmacokinetic and pharmacologic variation between different estrogen products
10. Estrogen replacement: The evolving role of transdermal delivery
11. Effects of transdermal versus oral hormone replacement therapy on bone density in spine and proximal femur in postmenopausal women
12. Long-term effects of transdermal and oral hormone replacement therapy on postmenopausal bone loss
13. Menorest®: Technical development and pharmacokinetic profile
14. Matrix delivery transdermal 17β-estradiol for the prevention of bone loss in postmenopausal women
15. A dose-ranging trial of a matrix transdermal 17β-estradiol for the prevention of bone loss in early postmenopausal women
16. 25 μg/day of transdermal estradiol and bone turn-over in late postmenopausal years
17. The effect of low-dose continuous estrogen and progesterone therapy with calcium and vitamin D on bone in elderly women. A randomized controlled trial
18. Low-dose esterified estrogen therapy: Effects on bone, plasma estradiol concentrations, endometrium, and lipid levels. Estratab/Osteoporosis Study Group
19. A combination of low doses of 17β-estradiol and norethisterone acetate prevents bone loss and normalizes bone turnover in postmenopausal women